MYCN and neuroblastoma: This data suggests that within the spectrum of available PI3K/mTOR pathway-active compounds, selective mTOR kinase inhibitors or dual inhibitors of PI3K and mTOR kinases are most likely to exhibit potent activity in neuroblastoma cells that express MYCN.